Welcome to our dedicated page for Stevanato Group S P A news (Ticker: STVN), a resource for investors and traders seeking the latest updates and insights on Stevanato Group S P A stock.
Stevanato Group S.p.A. (NYSE: STVN) is a global provider of drug containment, drug delivery, and diagnostic solutions for pharmaceutical, biotechnology, and life sciences companies. Its news flow, as reflected in recent press releases and SEC filings, centers on financial performance, capacity expansion, financing arrangements, and participation in healthcare investor conferences.
Investors following STVN news will find regular quarterly earnings announcements detailing revenue trends, segment performance for the Biopharmaceutical and Diagnostic Solutions and Engineering segments, margin evolution, and the growing contribution of high-value solutions such as high-performance Nexa® syringes and EZ-fill® vials and cartridges. These updates often include discussion of non-GAAP measures, capital expenditures, and liquidity.
News coverage also highlights strategic investments and footprint optimization, including expansions at manufacturing facilities in Cisterna di Latina and Fishers to increase pre-filled syringe and ready-to-use cartridge capacity, and enhancements at the Bad Oeynhausen, Germany, site for drug delivery system production. Financing news, such as the €200 million agreements with BNL BNP Paribas, Cassa Depositi e Prestiti, and Banco BPM, provides additional context on how Stevanato Group funds these projects.
In addition, Stevanato Group frequently announces its participation in major healthcare and investor conferences in locations such as New York, London, Las Vegas, Chicago, and Vienna. These events offer further insight into management’s views on market dynamics, high-value solutions, and long-term strategy.
By monitoring this page, readers can track Stevanato Group’s latest earnings releases, operational updates on capacity expansion and optimization plans, financing developments, and investor relations activities, all drawn from company-issued news and regulatory communications.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Stevanato Group (NYSE: STVN) announced it will release its Q1 2023 financial results on
The company will also provide a webcast of the discussion live, which will be archived for three months on its Investor Relations website. Stevanato Group, founded in 1949, is renowned for its solutions in drug containment and delivery across the pharmaceutical and life sciences sectors.
Stevanato Group (NYSE: STVN) has partnered with Thermo Fisher Scientific to introduce an innovative on-body drug delivery system. This semi-reusable device allows for micro-precision dosing and bolus injections, enhancing patient adherence by facilitating at-home administration of pharmaceuticals. The collaboration promises an end-to-end solution, combining Stevanato's EZ-fill® cartridges with Thermo Fisher's fill-and-finish services. This partnership not only accelerates time-to-market but also supports sustainability through reduced waste. Both companies aim to improve patient access to critical medications while meeting market demands swiftly.
Stevanato Group S.p.A. (NYSE: STVN) has announced a strategic collaboration with Recipharm, aiming to develop pre-fillable syringes for use in Recipharm’s soft mist inhalers. This partnership leverages Stevanato's 70+ years of manufacturing experience. The Alba® syringes will integrate with Recipharm's Pre-Filled Syringe Inhaler (PFSITM) technology, enhancing drug delivery for sensitive products. The combined offering promises efficient respiratory delivery and improved containment solutions for biopharma companies. This collaboration underscores Stevanato's commitment to supporting drug development from clinical phases to market release.
Stevanato Group (NYSE: STVN), a global provider of drug containment and delivery solutions, announced its participation in the Virtual KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 21 and March 22, 2023. The company will present on March 21 at 11:15 a.m. ET, with a live audio webcast available on their website. A replay will be accessible for approximately 90 days post-event. Founded in 1949, Stevanato Group offers an integrated portfolio of products and services across the drug life cycle, emphasizing research, technical innovation, and engineering excellence.
Summary not available.
Stevanato Group (NYSE: STVN) reported strong financial results for Q4 and FY 2022 and provided guidance for FY 2023. Q4 revenue rose 26% to €292.1 million, while FY 2022 revenue increased 17% to €983.7 million. Adjusted diluted EPS for Q4 were €0.19, and for FY 2022, €0.56. The company anticipates FY 2023 revenue between €1.085 billion and €1.115 billion and adjusted EPS of €0.58 to €0.62. Committed backlog grew 9% YoY to €957 million. Positive momentum was noted in high value solutions, accounting for 30% of revenue, with increased capital investments planned in the U.S. to meet demand.